I 
116TH CONGRESS 
1ST SESSION H. R. 4710 
To direct the Secretary of Defense to include in each national defense strategy 
steps to strengthen the United States industrial base and to assure 
an uninterrupted supply of medicines, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 17, 2019 
Mr. GARAMENDI (for himself and Mrs. HARTZLER) introduced the following 
bill; which was referred to the Committee on Armed Services, and in ad-
dition to the Committees on Veterans’ Affairs, and Financial Services, for 
a period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
A BILL 
To direct the Secretary of Defense to include in each national 
defense strategy steps to strengthen the United States 
industrial base and to assure an uninterrupted supply 
of medicines, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Pharmaceutical Inde-
pendence Long-Term Readiness Reform Act’’. 
VerDate Sep 11 2014 
04:15 Oct 23, 2019
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4710.IH
H4710
kjohnson on DSK79L0C42 with BILLS
SEC. 2. UNITED STATES MEDICINE SUPPLY CHAIN. 
(a) NATIONAL DEFENSE STRATEGY.—The Secretary 
of Defense shall include, in each national defense strategy 
under section 113(g) of title 10, United States Code, steps 
to be taken to assure the provision of medicines to enable 
combat readiness and force health protection. 
(b) REPORT TO CONGRESS.—Not later than one year 
after the date of the enactment of this Act, the Secretary 
of Defense, in consultation with the heads of other appro-
priate Federal departments and agencies, shall submit to 
Congress a report on vulnerabilities to the United States 
medicine supply chain. Such report shall include— 
(1) an identification of any finished drugs and 
their essential components including raw materials, 
chemical components and active ingredients nec-
essary for the manufacture of medicines whose sup-
ply is at risk of disruption during a time of war or 
national emergency; 
(2) an identification of shortages of finished 
drugs essential for combat readiness and force pro-
tection; 
(3) an identification of the defense and geo-
political contingencies that are sufficiently likely to 
arise that may disrupt, strain, compromise, or elimi-
nate supply chains of medicines and their essential 
VerDate Sep 11 2014 
04:15 Oct 23, 2019
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4710.IH
H4710
kjohnson on DSK79L0C42 with BILLS
components and recommendations for reasonable 
preparation for the occurrence of such contingencies; 
(4) an assessment of the resilience and capacity 
of the current supply chain and industrial base to 
support national defense upon the occurrence of the 
contingencies identified in paragraph (3), including 
with respect to— 
(A) the manufacturing capacity of the 
United States; 
(B) gaps in domestic manufacturing capa-
bilities including non-existent, extinct, threat-
ened, and single-point-of-failure capabilities; 
and 
(C) supply chains with single points of fail-
ure and limited resiliency; 
(5) legislative, regulatory, and policy changes 
necessary to avoid, or prepare for, contingencies 
identified in the report; and 
(6) recommendations to diversify supply away 
from complete dependency on sources of supply in 
competitor countries and politically unstable coun-
tries that may cut off United States supply, and ad-
dress critical bottlenecks and mitigate single points 
of failure and limited resilience. 
(c) PREFERENCE FOR MEDICINES.— 
VerDate Sep 11 2014 
04:15 Oct 23, 2019
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4710.IH
H4710
kjohnson on DSK79L0C42 with BILLS